Early Development & Drug Safety (EDDS) Community

Community Goals

Facilitate communication and collaboration amongst industry, academic, consultant and regulatory pharmacologists interested in early drug development and safety by:
  • Providing a venue for discussion and exchange of ideas amongst Community members at the Annual Meeting.
  • Supporting Community proposals for abstracts, workshops and symposia on early development and drug safety.
  • Promote advances in early drug development and safety by highlighting cutting edge approaches and hot topics in the scientific program and special sessions including webinars and pre-conferences.

Join the LinkedIn group

Past Webinars
The webinars below can be accessed in the Members Only Webinar Library: Access Library
  • Application of Artificial Intelligence/Machine Learning (AI/ML) Approaches to Support New Drug Development
  • Using Preclinical Data in Phase I Oncology Trials: A Bayesian Decision Theoretic Approach
  • Systems Pharmacology Modeling to Support Clinical Development of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody
  • First-in-Human Starting Dose Selection: Learnings from Survey by IQ MABEL Working Group and Experiences of the Regulatory Agency
  • Application of Quantitative Systems Toxicology in Drug Cardiovascular Safety Assessment
  • Safety Assessment in Phase 1 Healthy Volunteer Trials


Photo Gallery
Recent News
Contact Us